Candel's CAN-2409 Phase 3 Prostate Cancer Trial Shows 39% DFS Improvement in Extended Follow-up
CADL has more than doubled off its 52-week low of $4.35 on elevated volume (2.0× avg).
Summary
Candel Therapeutics announced highly positive extended follow-up data from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer. Presented at the AUA 2026 Annual Meeting, the data demonstrated a statistically significant and clinically meaningful 39% improvement in prostate cancer-specific disease-free survival (PCa-specific DFS) compared to placebo, after a median follow-up of 58 months. Consistent favorable trends were also observed across multiple secondary and exploratory endpoints, including time to biochemical failure and time to metastasis. This significant de-risking event for a late-stage asset is a major value driver for the clinical-stage biotech, following recent Q1 2026 financial results that showed a strong cash position. The positive data could lead to substantial investor confidence and a re-rating of the stock, with future catalysts including regulatory discussions and further data maturation.
At the time of this announcement, CADL was trading at $9.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642.4M. The 52-week trading range was $4.35 to $9.27. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.